Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBITDA: 2009-2019

Historic EBITDA for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2019 value amounting to $40.4 million.

  • Neurocrine Biosciences' EBITDA rose 137.63% to $22.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $36.5 million, marking a year-over-year decrease of 61.56%. This contributed to the annual value of $40.4 million for FY2019, which is 91.91% up from last year.
  • Per Neurocrine Biosciences' latest filing, its EBITDA stood at $40.4 million for FY2019, which was up 91.91% from $21.0 million recorded in FY2018.
  • In the past 5 years, Neurocrine Biosciences' EBITDA ranged from a high of $40.4 million in FY2019 and a low of -$144.1 million during FY2017.
  • Over the past 3 years, Neurocrine Biosciences' median EBITDA value was $21.0 million (recorded in 2018), while the average stood at -$27.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first slumped by 56.68% in 2016, then surged by 114.60% in 2018.
  • Over the past 5 years, Neurocrine Biosciences' EBITDA (Yearly) stood at -$89.6 million in 2015, then plummeted by 56.68% to -$140.4 million in 2016, then declined by 2.59% to -$144.1 million in 2017, then spiked by 114.60% to $21.0 million in 2018, then surged by 91.91% to $40.4 million in 2019.